Related Experiment Video
Updated: Jun 10, 2026

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
Published on: April 7, 2015
Research progress on the association between viruses and cardiac diseases
He-Min Yu1,2, Ming-Liang Zhu1, Yan-Li Zhao3
1School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, Yunnan, China.
None:
Virus-related cardiac diseases encompass a diverse spectrum of cardiovascular pathologies caused by direct viral infection and indirect immune-mediated injury. Major cardiotropic and cardioactive viruses-including severe acute respiratory syndrome coronavirus 2, influenza virus, human immunodeficiency virus, arboviruses (dengue virus, chikungunya virus, Zika virus), enteroviruses (coxsackievirus B3), and human cytomegalovirus-contribute to myocardial injury manifesting as myocarditis, pericarditis, arrhythmias, acute and chronic heart failure, and thromboembolic complications. Mechanisms of cardiac involvement are multifactorial, involving direct infection of cardiac cells leading to cytopathic effects and innate immune activation, dysregulated adaptive immune responses promoting myocardial inflammation and fibrosis, electrophysiological disturbances, and systemic effects such as endothelial dysfunction and prothrombotic states that precipitate ischemic events. Clinical manifestations range from subclinical injury to fulminant myocardial inflammation and may also include long-term sequelae, such as post-acute cardiovascular symptoms, as observed in long COVID cases. Therapeutic strategies emphasize early antiviral treatment when effective agents exist, judicious immunomodulation based on viral replication status, and supportive management of cardiac dysfunction and arrhythmias. Prevention through vaccination, personal protective measures, vector control, and optimization of cardiovascular risk factors remains pivotal to reduce the burden of virus-associated cardiovascular diseases. Future research requires improved diagnostic precision, mechanistic elucidation, and randomized trials to optimize antiviral and immunomodulatory interventions and to develop vaccines for currently unmet viral targets. An integrated, mechanism-informed approach across prevention, acute management, and long-term care is essential to mitigate the cardiovascular morbidity and mortality attributable to viral infections.
Related Concept Videos
Myocarditis III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy I: Introduction and Classification
Myocarditis I: Introduction
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Coronary Artery Disease II: Pathophysiology
